An ADHD drug with no known misuse potential, and a slow start
Most ADHD medicines are stimulants, with the misuse worries that come with them. Atomoxetine, sold as Strattera, is not one. Reviews find it works about as well as methylphenidate in children and adults, yet it has no known abuse liability. The catch is patience: benefits can take weeks to appear.
Atomoxetine was approved in the United States in 2002, and in 2023 it was filled more than 3 million times there, making it the 161st most prescribed drug. It is a selective norepinephrine reuptake inhibitor, taken by mouth, and approved for children aged six and over, teenagers and adults. It can be used on its own or together with a stimulant. Some evidence suggests it is less effective than lisdexamfetamine, and it is also used for cognitive disengagement syndrome, a condition that trials show responds poorly to methylphenidate.
The drug blocks the norepinephrine transporter across the brain, and in the prefrontal cortex it also indirectly raises dopamine. Its effects overlap with those of stimulants in roughly 70 to 80 percent of the brain regions involved. First benefits typically show after one to four weeks, full effect can need another two to four, and gains may keep building for a year or more. Doctors turn to it when stimulants cause troublesome side effects, fail to work, cost too much, or pose a risk for someone with a history of substance use.
It is not free of problems. Common effects include stomach pain, poorer appetite, nausea, tiredness and dizziness, along with small rises in heart rate and blood pressure. A 2020 meta-analysis rated it potentially the least preferred ADHD option on safety grounds. The American regulator carries a black box warning about suicidal thoughts and behaviour, and rare cases of liver injury have been reported. Because the liver enzyme CYP2D6 breaks it down, drugs such as paroxetine or bupropion that block that enzyme can multiply exposure several-fold.
Unlike stimulants, atomoxetine can be stopped suddenly without withdrawal effects, and unlike guanfacine or clonidine it does not produce significant withdrawal symptoms either. It also dampens the euphoric effects of dextroamphetamine in people. Beyond ADHD it has been studied for bedwetting in children, where it proved effective, and it is used off-label against excessive sleepiness, for example in narcolepsy.
Source: Atomoxetine
